Combining GLP-1 and Amylin Receptor Drugs Reduces Alcohol Drinking in Both Male and Female Rats

Adding salmon calcitonin (sCT, amylin receptor agonist) to ongoing dulaglutide (GLP-1R agonist) treatment reduced alcohol intake in both male and female rats without tolerance development. When sCT and dulaglutide were started simultaneously, an initial reduction in alcohol intake was observed in both sexes, but tolerance developed over time. Both treatment combinations consistently decreased food consumption and body weight in males and females. The treatment combination did not affect inflammatory mediators or receptor gene expression but did change fat tissue morphology.

Two separate alcohol-drinking experiments in rats of both sexes. Experiment 1: sCT was added to ongoing dulaglutide treatment (sequential approach). Experiment 2: sCT and dulaglutide were initiated simultaneously (concurrent approach). Outcomes measured included alcohol intake, food consumption, body weight, inflammatory mediators, amylin and GLP-1 receptor gene expression, and fat tissue morphology.

Alcohol use disorder (AUD) is a leading cause of preventable death with limited treatment options. The growing anecdotal and clinical evidence that GLP-1 drugs reduce alcohol cravings has generated enormous interest. This study takes the logical next step — combining two gut-brain peptide pathways (GLP-1 and amylin) to potentially enhance the anti-alcohol effect. The finding that treatment sequencing matters is practically important for clinical trial design.

The discovery that gut-brain peptides can modulate alcohol consumption connects the metabolic and addiction fields in unexpected ways. GLP-1 drugs are already in clinical trials for AUD, and amylin-based treatments are being developed for obesity. This study suggests that the combination could be more effective — but only with the right treatment sequence. As multi-receptor peptide drugs (like tirzepatide combining GIP/GLP-1) become available, adding amylin pathway activation could create a three-pronged approach to both obesity and addiction.

Rat alcohol-drinking models may not fully replicate human AUD patterns and motivations. Tolerance development with simultaneous treatment is concerning and would need to be addressed before clinical use. The study did not include a mechanistic analysis of why sequential addition worked better than simultaneous treatment. Specific dose-response relationships were not explored. The alcohol reduction effect was not compared to either drug alone as a single agent. Fat tissue morphology changes were observed but their significance is unclear.